SinuNase Effective For Severe, Chronic Sinusitis After All
This article was originally published in The Pink Sheet Daily
Executive Summary
Results make a compelling argument to partnering candidates, Accentia tells “The Pink Sheet” DAILY.
You may also be interested in...
Biovest Ends Therapeutic Cancer Vaccine Trial Early On Positive DMC Signal
Firm seeks “accelerated or conditional” approval path from FDA.
Accentia Chronic Sinusitis Candidate Fails Phase III Clinical Study
Disappointing trial data for intranasal lavage formulation sends Florida firm’s stock price tumbling by more than two-thirds.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.